INSMED INC Cash and Restricted Cash
INSMED INC (INSM) had Cash and Restricted Cash of $544.76 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $544.76M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $582.19M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $510.44M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $334.76M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $544.76M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $582.19M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $510.44M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $334.76M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $1.28B 10-Q · filed 2026-08-06 |
| 2025-03-31 | $403.25M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $555.03M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $461.45M 10-Q · filed 2025-10-30 |
| 2024-06-30 | $1.25B 10-Q · filed 2025-08-07 |
| 2024-03-31 | $595.73M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $482.37M 10-K · filed 2026-02-19 |
| 2023-09-30 | $487.11M 10-Q · filed 2024-10-31 |
| 2023-06-30 | $612.88M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $968.91M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $1.07B 10-K · filed 2026-02-19 |
| 2022-09-30 | $414.63M 10-Q · filed 2023-10-26 |
| 2022-06-30 | $416.08M 10-Q · filed 2023-08-03 |
| 2022-03-31 | $515.70M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $716.78M 10-K · filed 2025-02-20 |
| 2021-09-30 | $846.56M 10-Q · filed 2022-10-27 |
| 2021-06-30 | $928.33M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $409.75M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $532.76M 10-K · filed 2024-02-22 |
| 2020-09-30 | $588.75M 10-Q · filed 2021-10-28 |
| 2020-06-30 | $641.91M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $428.94M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $487.43M 10-K · filed 2023-02-23 |
| 2019-09-30 | $535.63M 10-Q · filed 2020-10-29 |
| 2019-06-30 | $601.26M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $420.23M 10-Q · filed 2020-04-30 |
| 2018-12-31 | $495.07M 10-K · filed 2022-02-17 |
| 2018-09-30 | $567.57M 10-Q · filed 2019-10-30 |
| 2018-06-30 | $634.33M 10-Q · filed 2019-08-01 |
| 2018-03-31 | $686.58M 10-Q · filed 2019-05-07 |
| 2017-12-31 | $381.17M 10-K · filed 2021-02-25 |
| 2016-12-31 | $162.59M 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |